RNA

Get tips on using Lipofectamine® 2000 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Human Cells - HESC Lipofectamine

Get tips on using TransIT-TKO Transfection Reagent to perform siRNA / RNAi /miRNA transfection Human Cells - Primary splenocytes Polymer / lipid

Get tips on using Lipofectamine® 2000 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Mouse - HeLa cells Lipofectamine

Get tips on using TransIT®-LT1 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Human Cells - HNSCC Polymer / Lipid

Get tips on using TransMessenger Transfection Reagent (0.5 ml) to perform siRNA / RNAi /miRNA transfection Mouse - Primary cortical and hippocampal cell

Get tips on using Lipofectamine® 2000 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Human Cells - A549 & LTEP-a-2 Lipofectamine

Get tips on using TransIT®-LT1 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Human Cells - Cal 27 cells Polymer / lipid

Get tips on using Lipofectamine® 2000 Transfection Reagent to perform siRNA / RNAi /miRNA transfection Mouse - Lung adenocarcenoma (A549/LTEP-a-2) Lipofectamine

The RNA-guided CRISPR-Cas9 nuclease system has revolutionized the genome editing practices. For the most part, the Cas9-mediated genome editing is performed either via nonhomologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, However, designing of specific sgRNAs and minimizing off-target cleavage mediated mutagenesis are the major challenges in CRISPR-Cas based genome editing. To circumvent these issues, we can take advantages of many available tools and approaches for sgRNA construction and delivery.

The RNA-guided CRISPR-Cas9 nuclease system has revolutionized the genome editing practices. For the most part, the Cas9-mediated genome editing is performed either via nonhomologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, However, designing of specific sgRNAs and minimizing off-target cleavage mediated mutagenesis are the major challenges in CRISPR-Cas based genome editing. To circumvent these issues, we can take advantages of many available tools and approaches for sgRNA construction and delivery.